Roland Windt1, Gerd Glaeske, Falk Hoffmann. 1. Centre for Social Policy Research (ZeS), University of Bremen, Mary-Somerville-Str. 3, 28359, Bremen, Germany, rwindt@zes.uni-bremen.de.
Abstract
BACKGROUND: Multiple sclerosis (MS) is an incurable disease of the central nervous system. In addition to symptomatic treatment, immunomodulatory and immunosuppressant agents are used to prevent attacks and to influence the course of disease. OBJECTIVE: The goal of this study was to assess the drug use of MS patients in outpatient care considering gender-related and regional differences. SETTING: We analyzed outpatient claims data of the single largest German health insurance fund (about 9 million insurants) for the year 2010. METHOD: Patients with MS were identified by outpatient ICD-10-GM-diagnosis code 'G35'. All age groups were included. MS-specific drug use was analysed for those patients, considering regional and gender-related differences in specific drug prescriptions. MAIN OUTCOME MEASURE: Prescription rates for symptomatic treatment, relapse treatment and disease-modifying treatment. RESULTS: 31,248 patients with a diagnosis of MS were identified (0.35 % of all insurants). Their mean age was 50.4 ± 14.1 years, 77.7 % of them were female. 37.6 % of the included patients were treated with disease-modifying drugs, 23.4 % got prescriptions for corticosteroids, drugs of choice for relapse therapy, and 63.1 % received symptomatic treatment as defined in the study. Women with MS were prescribed significantly more non-steroidal anti-inflammatory drugs, urinary antispasmodics, antidepressants, tranquilizer and hypnotic drugs. Regional variations were also found, with highest usage of disease-modifying drugs in eastern regions of Germany. CONCLUSION: This study gives an insight into the treatment of MS in daily practice by using the claims data of a large health insurance company. The prescription rate for disease modifying drugs was relatively low suggesting that early treatment was not routine practice. Furthermore, the results indicated that women with MS were more likely to receive treatment for psychiatric symptoms and pain.
BACKGROUND:Multiple sclerosis (MS) is an incurable disease of the central nervous system. In addition to symptomatic treatment, immunomodulatory and immunosuppressant agents are used to prevent attacks and to influence the course of disease. OBJECTIVE: The goal of this study was to assess the drug use of MSpatients in outpatient care considering gender-related and regional differences. SETTING: We analyzed outpatient claims data of the single largest German health insurance fund (about 9 million insurants) for the year 2010. METHOD:Patients with MS were identified by outpatient ICD-10-GM-diagnosis code 'G35'. All age groups were included. MS-specific drug use was analysed for those patients, considering regional and gender-related differences in specific drug prescriptions. MAIN OUTCOME MEASURE: Prescription rates for symptomatic treatment, relapse treatment and disease-modifying treatment. RESULTS: 31,248 patients with a diagnosis of MS were identified (0.35 % of all insurants). Their mean age was 50.4 ± 14.1 years, 77.7 % of them were female. 37.6 % of the included patients were treated with disease-modifying drugs, 23.4 % got prescriptions for corticosteroids, drugs of choice for relapse therapy, and 63.1 % received symptomatic treatment as defined in the study. Women with MS were prescribed significantly more non-steroidal anti-inflammatory drugs, urinary antispasmodics, antidepressants, tranquilizer and hypnotic drugs. Regional variations were also found, with highest usage of disease-modifying drugs in eastern regions of Germany. CONCLUSION: This study gives an insight into the treatment of MS in daily practice by using the claims data of a large health insurance company. The prescription rate for disease modifying drugs was relatively low suggesting that early treatment was not routine practice. Furthermore, the results indicated that women with MS were more likely to receive treatment for psychiatric symptoms and pain.
Authors: M Mäurer; R Dachsel; S Domke; S Ries; G Reifschneider; A Friedrich; P Knorn; H Landefeld; G Niemczyk; P Schicklmaier; C Wernsdörfer; S Windhagen; H Albrecht; S Schwab Journal: Eur J Neurol Date: 2010-12-29 Impact factor: 6.089
Authors: F Sellebjerg; D Barnes; G Filippini; R Midgard; X Montalban; P Rieckmann; K Selmaj; L H Visser; P S Sørensen Journal: Eur J Neurol Date: 2005-12 Impact factor: 6.089
Authors: Gisela Kobelt; Jenny Berg; Peter Lindgren; W G Elias; P Flachenecker; M Freidel; N König; V Limmroth; E Straube Journal: Eur J Health Econ Date: 2006-09
Authors: Peter Flachenecker; Kristin Stuke; Wolfgang Elias; Matthias Freidel; Judith Haas; Dorothea Pitschnau-Michel; Sebastian Schimrigk; Uwe K Zettl; Peter Rieckmann Journal: Dtsch Arztebl Int Date: 2008-02-15 Impact factor: 5.594
Authors: Ashutosh Malhotra; Michaela Gündel; Abdul Mateen Rajput; Heinz-Theodor Mevissen; Albert Saiz; Xavier Pastor; Raimundo Lozano-Rubi; Elena H Martinez-Lapiscina; Elena H Martinez-Lapsicina; Irati Zubizarreta; Bernd Mueller; Ekaterina Kotelnikova; Luca Toldo; Martin Hofmann-Apitius; Pablo Villoslada Journal: PLoS One Date: 2015-02-09 Impact factor: 3.240
Authors: Crystal Watson; Christine Prosser; Sebastian Braun; Pamela B Landsman-Blumberg; Erika Gleissner; Sarah Naoshy Journal: Clinicoecon Outcomes Res Date: 2017-02-01